复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

已收盘 04-25 16:09:09

12.000

+0.140

+1.18%

最高12.080	最低11.660	成交量307.59万
今开11.820	昨收11.860	日振幅3.54%
总市值320.69亿	流通市值66.23亿	总股本26.72亿
成交额3,678万	换手率0.56%	流通股本5.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":12,"timestamp":1714032549014,"preClose":11.86,"halted":0,"volume":3075877,"delay":0,"floatShares":551940500,"shares":2672398711,"eps":0.96320796,"marketStatus":"已收盘","marketStatusCode":5,"change":0.14,"latestTime":"04-25 16:09:09","open":11.82,"high":12.08,"low":11.66,"amount":36780007,"amplitude":0.035413,"askPrice":12,"askSize":28500,"bidPrice":11.94,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.9590613392132914,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714095000000},"adr":0,"adjPreClose":11.86,"dividendRate":0.024229,"openAndCloseTimeList":[[1714008600000,1714017600000],[1714021200000,1714032000000]],"volumeRatio":0.891862,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":22.88,"timestamp":1714028400000,"preClose":22.73,"halted":0,"volume":8754328,"delay":0,"premium":"-51.33"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2430465477","title":"复星医药(02196.HK)子公司治疗抗结核新药注册申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2430465477","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430465477?lang=zh_cn&edition=full","pubTime":"2024-04-25 00:30","pubTimestamp":1713976200,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司沈阳红旗制药自主研发的环丝氨酸胶囊，用于对该药敏感的结核菌引起且经一线抗结核药治疗效果不佳的活动性肺结核和肺外结核治疗的上市注册申请获国家药品监督管理局批准。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-24 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344772/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2429457023","title":"港股公告掘金 | 长城汽车第一季度归母净利约32.28亿元 同比增长1752.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429457023","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429457023?lang=zh_cn&edition=full","pubTime":"2024-04-24 23:02","pubTimestamp":1713970963,"startTime":"0","endTime":"0","summary":"【重大事项】商汤-W(00020)推出6000亿参数大模型“日日新5.0”中海石油化学(03983)斥资3.5亿元投资于中海信托设立的信托计划复星医药(02196)：环丝氨酸胶囊上市注册申请获批准君实生物(01877)：特瑞普利单抗上市许可申请获得香港卫生署药物办公室受理康方生物(09926)：国家药监局受理开坦尼用于一线治疗宫颈癌的新适应症上市申请联邦制药(03933)：阿莫西林克拉维酸钾片(规","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109422.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429437600","title":"复星医药：\n截至目前，健嘉医疗及其控股子公司/机构共有员工约2,000人","url":"https://stock-news.laohu8.com/highlight/detail?id=2429437600","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429437600?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:00","pubTimestamp":1713960059,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药04月24日在投资者关系平台上答复投资者关心的问题。投资者：请问2023年疫情板块产品，相关收入与2022年相比，这部分营业收入到底少了多少？不含新冠相关产品，2023年公司营业收入同比增长约12.43%。投资者：请问2023年并表的健嘉医疗及其附属子公司、医院员工总数有多少？截至目前，健嘉医疗及其控股子公司/机构共有员工约2,000人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400042234.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429543441","title":"复星医药：子公司环丝氨酸胶囊上市注册申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2429543441","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2429543441?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:20","pubTimestamp":1713957649,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，复星医药(600196)4月24日晚间公告，公司控股子公司沈阳红旗制药自主研发的环丝氨酸胶囊用于对该药敏感的结核菌引起的且经一线抗结核药（如链霉素、异烟肼、利福平和乙胺丁醇）治疗效果不佳的活动性肺结核和肺外结核（包括肾结核）治疗的上市注册申请近日获国家药监局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404243057803113.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404243057803113.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429143588","title":"复星医药(02196)：环丝氨酸胶囊上市注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2429143588","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429143588?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:22","pubTimestamp":1713954176,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，上海复星医药(集团)股份有限公司控股子公司沈阳红旗制药有限公司自主研发的环丝氨酸胶囊用于对该药敏感的结核菌引起的且经一线抗结核药(如链霉素、异烟肼、利福平和乙胺丁醇)治疗效果不佳的活动性肺结核和肺外结核(包括肾结核)治疗的上市注册申请于近日获国家药品监督管理局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108733.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430726428","title":"国内领先！复星诊断肝癌诊断试剂荣获“2023肿瘤标志物创新技术产品奖”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430726428","media":"复星医药","top":-1,"share":"https://www.laohu8.com/m/news/2430726428?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:26","pubTimestamp":1713950810,"startTime":"0","endTime":"0","summary":"4月20日，在中国肿瘤标志物学术大会中，中国抗癌协会肿瘤标志专业委员会联合中国抗癌协会肿瘤临床检验与伴随诊断专业委员会、中国抗癌协会肿瘤基因诊断专业委员会共同发布了“2023年度肿瘤标志物创新技术/产品奖”评选榜单，复星诊断核心岩藻糖基化低分子量激肽原检测试剂盒作为创新性肝癌辅助诊断产品，评选中荣获“肿瘤标志物创新技术产品三等奖”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417280287aa3677&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417280287aa3677&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430478626","title":"沈阳红旗制药：自主研发环丝氨酸胶囊获国家药品监督管理局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2430478626","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2430478626?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:22","pubTimestamp":1713950565,"startTime":"0","endTime":"0","summary":"快讯正文【复星医药成功研发新药 获国家药品监督管理局批准上市】复星医药公告，其控股子公司沈阳红旗制药有限公司自主创新研发的环丝氨酸胶囊已经获得国家药品监督管理局的官方批准，用于治疗对一线抗结核药物不敏感的结核病患者。该胶囊适用于结核菌引起的活动性肺结核及肺外结核（包括肾结核）的治疗。环丝氨酸胶囊的上市注册申请属于自主研发，标志着复星医药在抗结核药物领域的技术实力。复星医药表示，环丝氨酸胶囊的上市将增强其在抗结核药物市场的竞争力，为公司业绩增长带来新的增长点。公司将致力于提升产品质量，优化生产工艺，不断满足市场需求，助力中国抗结核药物研发事业的发展。下载和讯APP查看快讯，体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429828754","title":"复星医药(600196.SH)：控股子公司自主研发的环丝氨酸胶囊获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2429828754","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429828754?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:02","pubTimestamp":1713949347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司沈阳红旗制药有限公司自主研发的环丝氨酸胶囊(以下简称“该新药”)用于对该药敏感的结核菌引起的且经一线抗结核药(如链霉素、异烟肼、利福平和乙胺丁醇)治疗效果不佳的活动性肺结核和肺外结核(包括肾结核)治疗的上市注册申请于近日获国家药品监督管理局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108518.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429486036","title":"智通AH统计|4月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2429486036","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429486036?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:15","pubTimestamp":1713946505,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止4月24日收盘，东北电气、弘业期货、浙江世宝分列AH溢价率前三位，溢价率分别为1105.36%、762.40%、628.14%；招商银行、比亚迪股份、紫金矿业分列AH溢价率末三位，溢价率分别为21.27%、23.48%、23.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108407.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429116122","title":"创新高!复星医药(02196)入选全球药企管线规模前二十强","url":"https://stock-news.laohu8.com/highlight/detail?id=2429116122","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429116122?lang=zh_cn&edition=full","pubTime":"2024-04-23 17:42","pubTimestamp":1713865341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，全球知名咨询机构Citeline发布《2024年医药研发年度回顾》白皮书，并评选出全球TOP 25管线规模的制药公司，复星医药连续第三年入选，位列第17位，较上年度跃升7个名次。白皮书显示，2023年，全球新药研发管线规模再创新高，中国正不断巩固其世界第二大新药研发的市场地位，中美药企的创新管线规模数量差距正在不断缩小。同时，复星医药持续推动管线内疫苗的研发和产业化落地。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107603.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429877130","title":"大行花旗、瑞银、高盛等持续看好复星国际聚焦主业战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2429877130","media":"中金在线","top":-1,"share":"https://www.laohu8.com/m/news/2429877130?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:19","pubTimestamp":1713849541,"startTime":"0","endTime":"0","summary":"近日，复星国际在2023年度业绩公布后，接连获投资大行唱好。瑞银于3月底发表的研报，也看好复星国际聚焦主业的战略，指出未来复星将继续坚定执行退出非核心资产策略，集中资源于可持续的、可预测的、稳定的核心业务，力图在这些领域实现更高效的资源配置和利润增长。瑞银预计，随着中国经济增长动能的恢复、复星“瘦身健体”策略的继续执行，以及未来对股东的分红持续增加，复星国际的估值将进一步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231320518b48ebd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231320518b48ebd1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429546135","title":"肝素概念盘中跳水，千红制药跌0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429546135","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429546135?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:41","pubTimestamp":1713840086,"startTime":"0","endTime":"0","summary":"04月23日，肝素概念盘中跳水，截至10点41分，肝素概念整体指数下跌1.03%，报676.940点。从个股上来看，该概念的成分股中，千红制药跌0.84%，红日药业、复星医药、力生制药跌幅居前。从资金上来看，截止发稿，肝素概念主力净流入为-2858.15万，其中复星医药受到资金热捧，主力净流入684.62万；拉长时间线来看，该板块近20日主力资金净流入-8.18亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423104127861e80ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423104127861e80ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429948779","title":"复星医药(02196)：参与设立的投资基金完成私募投资基金备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2429948779","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429948779?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:43","pubTimestamp":1713778987,"startTime":"0","endTime":"0","summary":"安吉创新器械基金、徐州创新器械基金为平行基金，该等平行基金将在同时满足各自决策机制约定的条件下共同实施对外投资。近日，公司收到通知，安吉创新器械基金、徐州创新器械基金均已在中国证券投资基金业协会完成备案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042217441087a0dd85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042217441087a0dd85&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428655653","title":"将“颜值”转化为“产值” 豫园股份与菏泽共建“中国牡丹”产业研究室","url":"https://stock-news.laohu8.com/highlight/detail?id=2428655653","media":"中国财富网","top":-1,"share":"https://www.laohu8.com/m/news/2428655653?lang=zh_cn&edition=full","pubTime":"2024-04-19 19:50","pubTimestamp":1713527453,"startTime":"0","endTime":"0","summary":"4月17日，豫园股份旗下复星津美化妆品与山东省菏泽市牡丹发展服务中心正式签订战略合作协议，启动共建“中国牡丹”产业研究实验室，助力菏泽产业提升自主科创研发能力，以新质生产力开辟国内化妆品产业与花卉产业高质量发展新路径。此番“中国牡丹”产业研究实验室的创建进一步推动了“美丽经济”与“花样经济”的共鸣。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191959278795a2c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191959278795a2c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428096688","title":"复星减持Ageas股份 进退有序 聚焦深挖矿","url":"https://stock-news.laohu8.com/highlight/detail?id=2428096688","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428096688?lang=zh_cn&edition=full","pubTime":"2024-04-19 14:14","pubTimestamp":1713507277,"startTime":"0","endTime":"0","summary":"近期，复星在 保险 业务领域的一系列动作引发市场广泛关注。复星出售Ageas股份，将获得约6.26亿至6.70亿欧元的交易对价，并预计实现未经审计税前利润约6,000万至6,500万欧元，这不仅有助于其精简和优化投资组合，还能提升其财务表现与核心业务竞争力。复星聚焦主业“深挖矿”的战略成果，在其核心子公司核心业务上得到最为充分的体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191419428b39790c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191419428b39790c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428577419","title":"家庭医生概念盘中跳水，复星医药跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428577419","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428577419?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:25","pubTimestamp":1713493551,"startTime":"0","endTime":"0","summary":"04月19日，家庭医生概念盘中跳水，截至10点25分，家庭医生概念整体指数下跌1.02%，报819.310点。从个股上来看，该概念的成分股中，复星医药跌0.79%，福瑞股份、中国平安、思创医惠跌幅居前。从资金上来看，截止发稿，家庭医生概念主力净流入为-3.63亿，其中中元股份受到资金热捧，主力净流入298.64万；拉长时间线来看，该板块近20日主力资金净流入-68.76亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910255187e81fef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910255187e81fef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428835885","title":"干细胞概念盘中拉升，开能健康涨3.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428835885","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428835885?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:51","pubTimestamp":1713405088,"startTime":"0","endTime":"0","summary":"04月18日，干细胞概念盘中拉升，截至09点51分，干细胞概念整体指数上涨0.52%，报723.850点。从个股上来看，该概念的成分股中，开能健康涨3.26%，九 芝 堂、苏常柴Ａ、复星医药涨幅居前。从资金上来看，截止发稿，干细胞概念主力净流入为-2727.32万，其中复星医药受到资金热捧，主力净流入493.72万；拉长时间线来看，该板块近20日主力资金净流入-15.02亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809512887e8186c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809512887e8186c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428558583","title":"北向资金4月17日净买入复星医药24.57万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428558583","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428558583?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:30","pubTimestamp":1713403808,"startTime":"0","endTime":"0","summary":"4月17日, 北向资金增持复星医药24.57万股，连续3日增持。截止当日收盘，沪股通共持有复星医药4799.05万股，占流通股2.26%。沪股通增持金额前五个股分别为国电电力、大秦铁路、同仁堂、中国平安、赤峰黄金。复星医药近5个交易日下跌1.21%，沪股通累计增持33.59万股；近20个交易日下跌9.24%，沪股通累计增持47.02万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180930448b32443f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180930448b32443f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428397631","title":"复星医药(02196.HK)子公司药物获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2428397631","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428397631?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:49","pubTimestamp":1713347340,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，其子公司上海复宏汉霖生物技术股份有限公司(02696.HK) 近日收到国家药品监督管理局批准其自主研发的 HLX53（即抗 TIGIT 的Fc融合蛋白）联合汉斯状®（即斯鲁利单抗注射液）和汉贝泰®（即贝伐珠单抗注射液）一线治疗局部晚期或转移性肝细胞癌（HCC）开展临床试验。复宏汉霖拟于条件具备后，于内地开展相关治疗方案的II期临床试验。(vc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343032/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428397269","title":"复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428397269","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428397269?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:49","pubTimestamp":1713347340,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请，于近日获中国国家药品监督管理局受理。相关药物拟用于，获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎；以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月，集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343034/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0295},{"period":"1month","weight":-0.1042},{"period":"3month","weight":-0.2008},{"period":"6month","weight":-0.3389},{"period":"1year","weight":-0.4437},{"period":"ytd","weight":-0.3024}],"compareEarnings":[{"period":"1week","weight":0.0584},{"period":"1month","weight":0.0442},{"period":"3month","weight":0.061},{"period":"6month","weight":-0.0113},{"period":"1year","weight":-0.1232},{"period":"ytd","weight":0.009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.049465},{"month":2,"riseRate":0.75,"avgChangeRate":0.030196},{"month":3,"riseRate":0.666667,"avgChangeRate":0.05388},{"month":4,"riseRate":0.416667,"avgChangeRate":0.035793},{"month":5,"riseRate":0.454545,"avgChangeRate":0.026266},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.041074},{"month":7,"riseRate":0.545455,"avgChangeRate":0.017881},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.057829},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.025941},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035528},{"month":11,"riseRate":0.5,"avgChangeRate":0.052861},{"month":12,"riseRate":0.5,"avgChangeRate":0.024492}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}